# A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer

> **NCT01004250** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 109 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01004250
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2012-11
- **Final completion:** 2013-12
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2014-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01004250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01004250, "A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01004250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*